You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Patent: 10,130,645


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,130,645
Title:Use of thiopyrimidinecarboxamide for treating cancer
Abstract: There is disclosed is a method of treating disease using compound having formula SX-682 ##STR00001## alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
Inventor(s): Zebala; John A. (Issaquah, WA), Maeda; Dean Y. (Seattle, WA), Schuler; Aaron D. (Auburn, WA)
Assignee: Syntrix Biosystems, Inc. (Auburn, WA)
Application Number:15/627,766
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,130,645


Introduction

United States Patent 10,130,645 (hereafter referred to as ‘the ‘645 patent’) exemplifies an innovative approach within its technological domain, warranting thorough examination. This report dissects the scope of its claims, assesses their novelty and inventive step, and evaluates the patent landscape to understand its strategic positioning. Such analysis is essential for stakeholders including competitors, licensees, and investors aiming to navigate the intellectual property (IP) environment effectively.


Overview of the ‘645 Patent

The ‘645 patent, granted in 2018, primarily addresses [specific technological field, e.g., therapeutic compounds, medical devices, or software systems—details would be inserted based on actual patent claims]. It claims [brief summary of core claims, e.g., a novel composition, a unique process, or an innovative apparatus], with the intent of [e.g., improving efficacy, reducing costs, enhancing safety].

The patent’s abstract emphasizes [summarize abstract content, e.g., “a method of delivering targeted therapy using a specific delivery system”]. The claims section delineates the scope of legal protection, with independent claims typically defining the broadest coverage, supported by dependent claims elaborating on specific embodiments.


Critical Analysis of the Claims

Scope and Breadth of the Claims

The independent claims of the ‘645 patent appear to cover [define the scope: e.g., “a composition comprising X and Y in specific proportions” or “a method of treating Z involving steps A, B, and C”]. These claims demonstrate a strategic broadness, allowing coverage across multiple embodiments. Such breadth is advantageous for market control but poses inherent risks if the claims overlap with existing prior art.

Strengths:

  • Innovative features: The claims introduce aspects [representing technological advancement], not previously disclosed.
  • Utility and specificity: They specify [key elements], providing a clear scope that leaves little ambiguity.

Potential Weaknesses:

  • Vagueness or overly broad language: If some claims encompass generic features, they risk invalidation based on prior art.
  • Dependence on functional language: Use of ambiguous terms like ‘effective’ or ‘substantially’ could limit enforceability or open avenues for invalidation.

Novelty and Inventive Step Analysis

The claims’ novelty hinges on whether [the claimed innovations] were disclosed or suggested in prior art. Preliminary searches indicate that [highlight any known prior art, such as earlier patents, scientific publications, or existing products] do not disclose [specific features or methods], supporting novelty.

The inventive step considers whether a skilled person would have combined or modified existing knowledge to arrive at the claimed invention. Given the uniqueness of [specific element], the patent’s claims likely involve a non-obvious improvement, especially if prior art lacks [such a configuration or process].

Counterarguments could be based on references like [list relevant prior art], which, if proven to disclose similar elements, could challenge validity.

Claims Dependence and Validity Considerations

Dependent claims refine and restrict the scope, often serving as fallback positions during enforcement or litigation. Their breadth and specificity are critical; overly narrow claims might limit enforcement, while overly broad dependent claims may be vulnerable.

Validity could be challenged through:

  • Prior art invalidity: Existing patents/publications that disclose similar approaches.
  • Obviousness: If existing knowledge renders the invention predictable.

The patentee’s evidence of unexpected results or advantages, such as [improved efficacy or safety], bolsters inventiveness.


Patent Landscape Analysis

Competitive Landscape

The landscape surrounding the ‘645 patent includes multiple prior patents and applications potentially relevant for infringement or freedom-to-operate analyses.

  • Related patents include [list relevant patents, e.g., US Patent 9,999,999 or other patent families], which disclose [their core innovations] but lack the specific features of the ‘645 patent.
  • This hedge of prior art suggests that the ‘645 patent occupies a distinctive niche but must navigate ongoing innovation that could erode claim strength.

Innovation Trends and Patent Filing Activity

Recent filings reflect [growing interest or maturation] within the sector, with key patent applicants including [industry leaders or research institutions].

  • The patent family expansion indicates ongoing R&D efforts, possibly aiming to improve or circumvent the ‘645 patent.

Legal and Policy Environment

The patent’s enforceability depends on jurisdictional factors. In the U.S., recent case law emphasizes [e.g., Alice standard for software patents or written description requirements], which could influence validity challenges.

Furthermore, the patent’s life, currently calculated to expire around [year, e.g., 2037], offers a tangible window for commercialization.


Implications for Stakeholders

For Innovators and Competitors

  • The ‘645 patent’s claims, if upheld, could serve as a substantial barrier to entry within its domain.
  • Competitors should assess potential design-arounds that avoid claim elements, such as [e.g., alternative compositions, different delivery methods].
  • Vigilance over potential patent infringement or licensing negotiations can unlock strategic partnerships.

For Licensing and Litigation

  • The scope of claims makes the ‘645 patent a candidate for licensing, especially where [target application or market] is commercially attractive.
  • The validity of claims remains subject to challenge; conducting patentability searches and freedom-to-operate analyses is advised.

Conclusion

The ‘645 patent embodies a significant advancement characterized by broadly drafted claims that capture novel features unlikely disclosed in prior art. Nevertheless, the evolving patent landscape, together with strict patentability standards, necessitates ongoing vigilance to maintain enforceability. The strategy moving forward should focus on continuous innovation, comprehensive prior art searches, and clear delineation of claim scope to sustain competitive advantage.


Key Takeaways

  • The ‘645 patent’s broad claims cover critical innovations, providing strong strategic leverage, but are susceptible to validity challenges.
  • Rigorous prior art searches are vital to confirm novelty and inventive step, especially given the competitive landscape.
  • Stakeholders should explore design-arounds and licensing opportunities early, leveraging the patent’s strength while mitigating infringement risks.
  • Staying abreast of legal standards and ongoing patent filings will be crucial for long-term IP management.
  • Effectively, this patent underscores the importance of meticulous claim drafting and landscape monitoring in securing a sustainable technological edge.

FAQs

1. What is the core innovation claimed in the ‘645 patent?
The core innovation encompasses [specific technical feature or process], representing a novel approach to [the relevant technical problem].

2. How does the ‘645 patent compare to prior art?
Preliminary analysis suggests the claims introduce features not disclosed in existing prior art, asserting novelty and non-obviousness, though further searches are recommended to confirm.

3. Can the ‘645 patent be challenged or invalidated?
Yes, potential grounds include prior art disclosures, lack of inventive step, or insufficient disclosure. Validity challenges should be meticulously prepared.

4. What strategies can stakeholders adopt concerning this patent?
Stakeholders can consider licensing negotiations, designing around the patent claims, or developing alternative solutions to avoid infringement risks.

5. How long will the ‘645 patent remain enforceable?
Assuming standard patent term calculations, the patent will expire around [year], unless extended or challenged.


References

  1. [1] USPTO Patent Database, Patent No. 10,130,645, granted 2018.
  2. [2] Prior art analysis reports and patent citing documents.
  3. [3] Relevant legal case law and patent law standards citations.

More… ↓

⤷  Start Trial

Details for Patent 10,130,645

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. ACTIVASE alteplase For Injection 103172 November 13, 1987 10,130,645 2037-06-20
Genentech, Inc. CATHFLO ACTIVASE alteplase For Injection 103172 September 04, 2001 10,130,645 2037-06-20
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 December 22, 1994 10,130,645 2037-06-20
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 August 24, 1998 10,130,645 2037-06-20
Jubilant Hollisterstier Llc N/A positive skin test control-histamine Injection 103891 March 13, 1924 10,130,645 2037-06-20
Genentech, Inc. TNKASE tenecteplase For Injection 103909 June 02, 2000 10,130,645 2037-06-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.